<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03928249</url>
  </required_header>
  <id_info>
    <org_study_id>SaoPSU12</org_study_id>
    <nct_id>NCT03928249</nct_id>
  </id_info>
  <brief_title>Therapeutic Intervention of Eriocitrin in the Reduction of Hyperglycemia in Pre-diabetic Individuals</brief_title>
  <official_title>Therapeutic Intervention of Eriocitrin in Reducing Hyperglycemia in Pre-diabetic Subjects: Double-blind, Randomized, Placebo-controlled Crossover Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>São Paulo State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>São Paulo State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Supplementation with citrus bioflavonoids (hesperidin, naringin, diosmin and eriocitrin,&#xD;
      among others) has been associated with an improvement in the glycidic and lipid profile,&#xD;
      reduction of insulin resistance and systemic inflammation, and reduction of endothelial&#xD;
      damage. This study aims to evaluate the effects of eriocitrin supplementation on the&#xD;
      metabolic parameters of pre-diabetic individuals. Participants will be adults with&#xD;
      pre-diabetes who will receive 200 mg / d of eriocitrin. Before, during and after treatment,&#xD;
      anthropometric measures (weight, body composition and circumferences), biochemical (lipid and&#xD;
      glucose profile, inflammatory parameters, endothelial markers, liver function, renal&#xD;
      function) will be evaluated. Metabolic parameters that constitute risk factors for diabetes&#xD;
      and associated chronic diseases are expected to be improved by supplementation with&#xD;
      eriocitrin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals aged 35-60 years and who present at least one of the following criteria: (1)&#xD;
      increased fasting blood glucose from 6.1 to 7.0 mmol / L, (2) decreased glucose tolerance of&#xD;
      7 , 8 to 11.1 mmol / L, and (3) glycated hemoglobin with values between 5.7 and 6.4% 10 will&#xD;
      be eligible to participate in this study. The exclusion criteria will be to use hypoglycemic,&#xD;
      hypolipidemic drugs, dietary supplements (vitamins, minerals, bioflavonoids, prebiotics,&#xD;
      probiotics or other bioactive compounds), exercise intensely (more than 10 hours per week),&#xD;
      history of cardiovascular diseases , diabetes mellitus, liver and kidney disease.&#xD;
&#xD;
      The selected individuals will be distributed randomly in 2 groups through random number&#xD;
      generator program. Group A (n = 20) will receive 200 mg / d of eriocitrin for 12 weeks, with&#xD;
      washout for 2 weeks and then receive 200 mg / d of placebo for 12 weeks; group B (n = 20)&#xD;
      will receive 200 mg / d placebo for 12 weeks with washout for 2 weeks and then receive 200 mg&#xD;
      / d placebo for 12 weeks.&#xD;
&#xD;
      The primary endpoint will be fasting blood glucose, blood glucose 2 hours after oral glucose&#xD;
      tolerance test (GTTO), and HbA1c. The secondary endpoint will be insulin, HOMA-IR, total&#xD;
      cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, ALP, yGT, AST, ALT, TNF-α,&#xD;
      IL-6, CRP, body weight, body mass index BMI), muscle mass, fat mass, body fat and waist-hip&#xD;
      ratio, and macronutrient intake.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Actual">October 22, 2020</completion_date>
  <primary_completion_date type="Actual">June 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting glycemia</measure>
    <time_frame>0-12-18-26 week</time_frame>
    <description>Changes in serum glycemia concentration before and after administration of the intervention/placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change in plasma glucose concentration</measure>
    <time_frame>0-12-18-26 week</time_frame>
    <description>Changes in serum 2 hours after oral glucose tolerance test (mg/dL) before and after administration of the intervention / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in plasma HbA1c</measure>
    <time_frame>0-12-18-26 week</time_frame>
    <description>Changes in serum HbA1c (%) before and after administration of the intervention / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in plasma insulin concentration</measure>
    <time_frame>0-12-18-26 week</time_frame>
    <description>Changes in serum insulin (µU/mL) before and after administration of the intervention / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in plasma lipid concentration</measure>
    <time_frame>0-12-18-26 week</time_frame>
    <description>Changes in serum cholesterol (mg/dL), triglycerides (mg/dL),HDL-C(mg/dL), LDL-C(mg/dL) before and after administration of the intervention/placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in plasma hepatic enzymes</measure>
    <time_frame>0-12-18-26 week</time_frame>
    <description>Changes in ALT (U/L), AST (U/L), ALP (U/L), GGT (U/L) before and after administration of the intervention / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in plasma inflammatory parameters</measure>
    <time_frame>0-12-18-26 week</time_frame>
    <description>Changes in CRP (mg/dL), TNF-a (mg/dL), IL-6 (mg/dL) before and after administration of the intervention / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in anthropometric parameters</measure>
    <time_frame>0-12-18-26 week</time_frame>
    <description>Changes in body weight (Kg), muscle mass (Kg), fat mass (Kg) before and after administration of the intervention / placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pre Diabetes</condition>
  <arm_group>
    <arm_group_label>Grupo A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A (n = 20) will receive 200 mg / d of eriocitrin for 12 weeks, washout for 2 weeks and then receive 200 mg / d of placebo for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GRUPO B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>group B (n = 20) will receive 200 mg / d placebo for 12 weeks with washout for 2 weeks and then receive 200 mg / d placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eriocitrin</intervention_name>
    <description>A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed.&#xD;
Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara)&#xD;
At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio.</description>
    <arm_group_label>GRUPO B</arm_group_label>
    <arm_group_label>Grupo A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  35-60 years&#xD;
&#xD;
          -  Increased fasting blood glucose from 6.1 to 7.0 mmol / L or,&#xD;
&#xD;
          -  Decreased glucose tolerance of 7 , 8 to 11.1 mmol / L or,&#xD;
&#xD;
          -  Glycated hemoglobin with values between 5.7 and 6.4%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use hypoglycemic, hypolipidemic drugs,&#xD;
&#xD;
          -  Use dietary supplements (vitamins, minerals, bioflavonoids, prebiotics, probiotics or&#xD;
             other bioactive compounds),&#xD;
&#xD;
          -  Exercise intensely (more than 10 hours per week)&#xD;
&#xD;
          -  History of cardiovascular diseases , diabetes mellitus, liver and kidney disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thais B Cesar, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sao Paulo State University &quot;Julio de Mesquita Filho&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sao Paulo State University &quot;Julio de Mesquita Filho&quot;</name>
      <address>
        <city>Araraquara</city>
        <state>São Paulo</state>
        <zip>14800-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2019</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>São Paulo State University</investigator_affiliation>
    <investigator_full_name>Thais Cesar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Eriocitrin</keyword>
  <keyword>Citrus bioflavonoids</keyword>
  <keyword>Flavanone</keyword>
  <keyword>Pre-diabetes</keyword>
  <keyword>Blood glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

